Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Blood (2019) 134 (Supplement_1): 4161.

https://doi.org/10.1182/blood-2019-127923

Published: 2019

Journal Articles

Incidence, Clinical Characteristics and Outcome of Cardiac Toxicity in Elderly Patients with Diffuse Large B-Cell Lymphoma

Wei Ping Liu, Yan Feng Xu, Yan Xie, Xiaopei Wang, MD, Yuqin Song, MD PhD, Jun Zhu, MD PhD

Blood (2018) 132 (Supplement 1): 5416.

https://doi.org/10.1182/blood-2018-99-117955

Published: 2018

Journal Articles

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

M. Judith Peterschmitt, MD, Selena Freisens, MD, Audrey W Hou, PharmD, Lisa Underhill, MS, Meredith C. Foster, ScD, Sebastiaan J.M. Gaemers, MD

Blood (2018) 132 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2018-99-118319

Published: 2018

Journal Articles

Antithrombotic Therapy Management in Patients with Inherited Bleeding Disorders and Ischaemic Heart Disease: A Single-Center Experience

Marie-Léa Piel-Julian, Marie-Françoise Thiercelin-Legrand, MD, Guillaume Moulis, MD PhD, Sophie Voisin, MD, Ségolène Claeyssens, Laurent Sailler, MD PhD

Blood (2018) 132 (Supplement 1): 1213.

https://doi.org/10.1182/blood-2018-99-117101

Published: 2018

Journal Articles

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Blood (2018) 132 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2018-99-111369

Published: 2018

Journal Articles

Symptomatic Hemoglobin New Mexico and a Case of Therapeutic Benefit with Acetazolamide

Ahmed Ayad, MD, Sara Nofal, MD, Crystal Jobson, MD, Yuval Raizen, MD, Mona Lisa Alattar, MD

Blood (2018) 132 (Supplement 1): 4918.

https://doi.org/10.1182/blood-2018-99-119250

Published: 2018

Journal Articles

The Advantage of Video Assisted Education before Intrathecal Chemotherapy on Anxiety Level and Knowledge Transfer

Abdullah Bany Hamdan, BSN, RN, MSc, Walid Ballourah, MD, Sami Alshammary, MD, Sherwynn Javison, Richard Erlandez, Assem Elghazaly, MD, Musa AlHarbi, MD

Blood (2017) 130 (Supplement 1): 5619.

https://doi.org/10.1182/blood.V130.Suppl_1.5619.5619

Published: 2017

Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Blood (2017) 130 (Supplement 1): 899.

https://doi.org/10.1182/blood.V130.Suppl_1.899.899

Published: 2017

Journal Articles

Dexpramipexole As a Steroid-Sparing Agent in Hypereosinophilic Syndromes (HES): An Open-Label Proof-of-Concept Study

Sandhya R. Panch, MD MPH, Michael Bozik, MD, Thomas Brown, RN, Ulrike Demarco, Dipl. Biol., Jamie Hahn, BS, Alexander Komarov, PhD, Tamika Magee, RN, Michelle Makiya, RN, Calman Prussin, MD, Armando Signore, PhD, Mary Sullivan, BA, Lauren Wetzler, MHS, PA, Cynthia E. Dunbar, MD, Steven Dworetzky, PhD, Irina Maric, MD, Amy D Klion, MD

Blood (2016) 128 (22): 1327.

https://doi.org/10.1182/blood.V128.22.1327.1327

Published: 2016

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T Cells Improve Responses to Chemotherapy-Refractory Mantle Cell Lymphoma: A Case Report

Weihong Chen, MD, Xin Du, Changru Luo, Qiaoxia Zhang, Mingjun Wang

Blood (2016) 128 (22): 5393.

https://doi.org/10.1182/blood.V128.22.5393.5393

Published: 2016

Journal Articles

The First Case of Primary Cardiac Lymphoma, Diffuse Large B-Cell Type, Successfully Treated with EPOCH-R

Sherise Chantell Rogers, MD MPH, Owen A. O'Connor, MD PhD, Glen Granati, MD, Kavitha Yaddanapudi, MD

Blood (2016) 128 (22): 5418.

https://doi.org/10.1182/blood.V128.22.5418.5418

Published: 2016

Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z Badros, MD, Elizabeth Hyjek, MD PhD, Ning Ma, Alexander M. Lesokhin, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Ashlee Johnson, Cameron Dell, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2016) 128 (22): 490.

https://doi.org/10.1182/blood.V128.22.490.490

Published: 2016

Journal Articles

A Study of Symptom Burdens Related to Chemotherapy-Induced Anemia in Patients Diagnosed with Breast Cancer, Lung Cancer and Non-Hodgkin Lymphoma

Chun Chao, PhD, Leila Family, PhD MPH, Kimberly Cannavale, MSc, Andrew Pourmoussa, MD, Lanfang Xu, MSc, Mehta Bhakti, MD, Hairong Xu, MD PhD

Blood (2016) 128 (22): 5980.

https://doi.org/10.1182/blood.V128.22.5980.5980

Published: 2016

Journal Articles

Challenges of Assessing Symptom Burden in Patients with Haematological Malignancies

Tatyana Ionova, PhD, Tatyana Nikitina, MD PhD

Blood (2016) 128 (22): 2369.

https://doi.org/10.1182/blood.V128.22.2369.2369

Published: 2016

Journal Articles

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Matthew S. Davids, Haesook T. Kim, PhD, Alyssa Nicotra, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Hari P. Miskin, MS, Peter Sportelli, Asad Bashey, MD PhD, Laura Stampleman, MD, Jens Rueter, MD, Adam Boruchov, MD, Jon Arnason, MD, Caron A. Jacobson, MD, David C. Fisher, MD, Jennifer R. Brown

Blood (2016) 128 (22): 641.

https://doi.org/10.1182/blood.V128.22.641.641

Published: 2016

Journal Articles

Primary Cardiac Burrkit Lymphoma: Characteristics, Clinical Presentation and Outcome

Mohamed Jumayli, MD, Emily Chen, MD, Hossein Sadrzadeh, MD

Blood (2015) 126 (23): 5048.

https://doi.org/10.1182/blood.V126.23.5048.5048

Published: 2015

Journal Articles

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z. Badros, MD, Mehmet H. Kocoglu, MD, Ning Ma, NP, Aaron P. Rapoport, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Cameron Dell, Nancy M. Hardy, MD, Jean Yared, MD, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2015) 126 (23): 506.

https://doi.org/10.1182/blood.V126.23.506.506

Published: 2015

Journal Articles

Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina

Ana Inés Varela, MD, Romina Laura Penalba, Alicia Enrico, MD, Marta Catalan, Maria Veronica Ventriglia, Maria Josefina Freitas, Carolina Pavlovsky, MD, Susana Garbiero, PhD, Martin Beccasese, MD, Raquel Maria Nelida Bengio, MD, Catalina Abramovich, MD, Miguel A Pavlovsky, MD, Elena Beatriz Moiraghi, MD

Blood (2015) 126 (23): 5149.

https://doi.org/10.1182/blood.V126.23.5149.5149

Published: 2015

Journal Articles

Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML)

Simone Claudiani, Nikhita Gupta, BSc, Ji Soo Baik, BSc, Simona Deplano, MDPhD, Renuka Palanicawander, Gareth Gerrard, Alistair G Reid, BSc, PhD, Richard M Szydlo, BSc, PhD, Dragana Milojkovic, Letizia Foroni, Jane F. Apperley, MD

Blood (2015) 126 (23): 2794.

https://doi.org/10.1182/blood.V126.23.2794.2794

Published: 2015

NARROW

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Incidence, Clinical Characteristics and Outcome of Cardiac Toxicity in Elderly Patients with Diffuse Large B-Cell Lymphoma

The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials

Antithrombotic Therapy Management in Patients with Inherited Bleeding Disorders and Ischaemic Heart Disease: A Single-Center Experience

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Symptomatic Hemoglobin New Mexico and a Case of Therapeutic Benefit with Acetazolamide

The Advantage of Video Assisted Education before Intrathecal Chemotherapy on Anxiety Level and Knowledge Transfer

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Dexpramipexole As a Steroid-Sparing Agent in Hypereosinophilic Syndromes (HES): An Open-Label Proof-of-Concept Study

Anti-CD19 Chimeric Antigen Receptor T Cells Improve Responses to Chemotherapy-Refractory Mantle Cell Lymphoma: A Case Report

The First Case of Primary Cardiac Lymphoma, Diffuse Large B-Cell Type, Successfully Treated with EPOCH-R

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

A Study of Symptom Burdens Related to Chemotherapy-Induced Anemia in Patients Diagnosed with Breast Cancer, Lung Cancer and Non-Hodgkin Lymphoma

Challenges of Assessing Symptom Burden in Patients with Haematological Malignancies

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Primary Cardiac Burrkit Lymphoma: Characteristics, Clinical Presentation and Outcome

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina

Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only